Gossamer Bio, Inc.

For the period ended Dec 31, 2025. Filed Mar 17, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 17, 2026

GOSS$11.28+6.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

	Year Ended December 31,
	2025	2024	2023
Revenue:
Revenue from sale of licenses	$—	$90,682	$—
Revenue from contracts with collaborators	48,471	24,019	—
Total revenue	48,471	114,701	—
Operating expenses:
Research and development	174,093	138,487	135,304
In process research and development	7,475	—	10,000
General and administrative	37,631	36,133	38,455
Total operating expenses	219,199	174,620	183,759
Loss from operations	(170,728)	(59,919)	(183,759)
Other income (expense)
Interest income	1,970	1,779	1,997
Interest expense	(10,989)	(11,517)	(13,511)
Other income, net	9,289	14,022	15,456
Total other income, net	270	4,284	3,942
Loss before provision (benefit) for income taxes	(170,458)	(55,635)	(179,817)
Provision (benefit) for income taxes	(88)	893	—
Net loss	$(170,370)	$(56,528)	$(179,817)
Other comprehensive income (loss):
Foreign currency translation	(6,248)	1,450	33
Unrealized income (loss) on marketable securities	(90)	89	191
Other comprehensive income (loss)	(6,338)	1,539	224
Comprehensive loss	$(176,708)	$(54,989)	$(179,593)
Net loss per share, basic and diluted	$(0.75)	$(0.25)	$(1.18)
Weighted average common shares outstanding, basic and diluted	228,519,130	226,228,016	152,621,669

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.